Strategy Case Analysis Merck & Co.: Evaluating a Drug Licensing Opportunity Introduction: Davanrik is a new drug developed by LAB Pharmaceuticals‚ which has the potential to treat depression and obesity. Davanrik was initially developed to treat depression by stimulating the receptor in the serotonin system that promotes anti-depression. However‚ it was discovered that Davanrik also blocks the receptor that causes hunger. LAB Pharmaceuticals obtained a patent for Davanrik with a max remaining
Premium
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions:
Premium Decision theory Probability theory Decision tree
3rd‚ 2014 Case 5: Merck‚ the FDA‚ and the Vioxx Recall Section I Merck was one of the world’s leading pharmaceutical firms. The company ranked 4th I sales after Pfizer and Johnson & Johnson and it ranked 5th in assets and market value. Merck ranked 1st in profits‚ earning $7.33 billion on $30.78 billion in sales. In 2006‚ Merck faced major challenges with their once best selling prescription painkillers‚ Vioxx which was pulled off the market in September of 2004 after Merck learned it increased
Free Pharmacology Food and Drug Administration
patent. In 1995‚ Merck entered into a licensed agreement and collaboration to hold the rights to market Gardisil in all countries accept Australia and New Zealand. Merck was invested heavily in Gardasil‚ spending $1.2 billion in fifteen years before seeking approval from the FDA. After results of all phase trials were impressive‚ Merck moved for FDA approval. Merck hoped to receive approval before a competitive drug‚ known as Cervarix was approved. If so‚ it would guarantee Mercks first mover advantage
Premium Human papillomavirus HPV vaccine Cervical cancer
Assignment 023 Age Physical Development Intellectual and cognitive development Communication Development Social‚ emotional and behavioural development Moral development 0-3 months *Legs not yet strong enough for holding weight when standing. * Will hold rattle for a few moments‚ but cannot usually look at it‚ at the same time. * Can hold head up for several seconds. Head and chest lifts when lying on tummy. (tummy time) * Rests weight on hands and using them to explore *Hands open. Arm movements
Premium Jean Piaget Child development Developmental psychology
Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23‚ 2011 Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result
Premium Mergers and acquisitions Due diligence
Merck (MRK) experienced only minute changes over the period that I held onto it. During this time‚ Merck experienced both positives and negatives‚ and these different experiences helped to balance the value of the company’s stock. At the beginning of the year‚ Merck successfully “acquired IOmet‚” a company that produces “innovative medicines for the treatment of cancer.” With this new subsidiary‚ Merck will most likely experience an increase in profits
Premium Balance sheet Financial ratios Generally Accepted Accounting Principles
The actions Merck undertook when marketing Vioxx and emphasizing its safety even after finding out the product’s side effects endangered all its key stakeholders and showed the real face of the company that accented its highly ethical maxims. Cardiovascular side effects of the Vioxx increased the risk of complications that could have caused patient’s death‚ therefore Merck violated the basic right to life of all the Vioxx consumers. It was already mentioned that Vioxx caused 3468 deaths by heart
Premium Enron Business ethics Ethics
Assignment 023 Understand Child and Young Person Development Table 1: Physical development Age range Explain the sequence and rate of development 0-3 months When born‚ babies show innate reflexes‚ such as swallowing and sucking‚ rooting reflex‚ grasp reflex‚ startle reflex‚ walking and standing reflex; in the first month babies become less curled up and the startle reflex is starting to fade; toward the end of the third month babies start lifting and turning their heads. 3-6 months
Premium Developmental psychology Jean Piaget Childhood
Should Merck license the compound? Merck would be responsible for 1) the approval of Davanrik 2) the manufacture of Danavrik 3) marketing of Danavrik Merck would pay LAB for 1) initial fee 2) royalty on all sales 3) make additional pymts as Danavrik completed each stage of approval process (3 Phases) Additional facts: approval process should take 7 years patent will cover 17 years (7 of approval process nad 10 yr period of exclusivity beginning in yr 7) 1 Assumptions: All Cash flows
Premium Decision tree Arithmetic mean Variance